Country: Australia
Language: English
Source: APVMA (Australian Pesticides and Veterinary Medicines Authority)
TRILOSTANE - MICRONISED
DECHRA LTD
trilostane(30mg/Cp)
ORAL CAPSULE
TRILOSTANE - MICRONISED HORMONE Active 30.0 mg/Cp
#30; #capsules
VM - Veterinary Medicine
DOG | BITCH | CASTRATE | PUPPY
ENDOCRINE SYSTEM
CUSHINGS DISEASE | HYPERADRENOCORTISISM | PITUITARY DEPENDENT HYPERDRENO
Poison schedule: 4; Withholding period: WHP: N/A; Host/pest details: DOG: [CUSHINGS DISEASE]; For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing's syndrome) in dogs.Contraindications, Precautions, etc: See label.
Registered
2023-07-01
For Official Use Only E-LABEL APPLICATION (DRAFT) COMPANY NAME: DERMCARE-VET PTY. LTD PRODUCT NAME: VETORYL 30 MG CAPSULES ELABEL APPLICATION NO: DC14-54857834E117 APVMA APPROVAL NO: 60620/102544 PRODUCT NO: 60620 VERSION NO: 4.0 APPLICATION STARTED: 2015-May-04 15:00:57 VERSION CREATED: 2015-Oct-28 10:58:10 STARTED BY: Yvette Risk PRINTED: 2015-Oct-28 11:21:30 LABEL NAME: VETORYL 30 MG CAPSULES SIGNAL HEADINGS: PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY CONSTITUENT STATEMENTS: Each capsule contains 30 mg TRILOSTANE CLAIMS: For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing’s syndrome) in dogs. NET CONTENTS: 30 capsules DIRECTIONS FOR USE: RESTRAINTS: CONTRAINDICATIONS: This product is contraindicated in animals suffering from primary hepatic disease and/or renal insufficiency. This product is contraindicated in pregnant or nursing bitches or in any animals intended for breeding. This product is contraindicated in dogs weighing less than 3 kg. PRECAUTIONS: An accurate diagnosis of hyperadrenocorticism is essential. As the majority of cases of hyperadrenocorticism are diagnosed in dogs between the ages of 10-15 years, other pathological processes are frequently present. It is particularly important to screen cases for primary hepatic disease and renal insufficiency as the product is contraindicated in these cases. The presence of diabetes mellitus and hyperadrenocorticism together requires specific monitoring. If a dog has previously been treated with mitotane, its adrenal function will have been reduced. Experience in the field suggests that an interval of at least a month should elapse between cessation of mitotane and the introduction of trilostane. Close monitoring of adrenal function is advised, as dogs may be more susceptible to the effects of trilostane. RLP APPROVED For Official Use Only The product should be used with extreme caution in dogs with pre-existing anaemia as further reductions in packed-cell volume and haemoglo Read the complete document
MATERIAL SAFETY DATA SHEET DATE ISSUED: 1 MAY 2012 VERSION: 01 PAGE 1 OF 4 VETORYL ® CAPSULES PRODUCT NAME VETORYL ® 10MG, 30MG, 60MG OR 120MG CAPSULES OTHER NAME(S) SUPPLIER NAME DERMCARE-VET PTY LTD ADDRESS 22 Aranda St, Springwood, QLD, AUSTRALIA, 4127 TELEPHONE (07) 3387 9700 FAX (07) 3208 3965 EMERGENCY (07) 3387 9700 (Monday – Friday, 9:00am – 5:00pm) EMAIL dermcare@dermcare.com.au WEB SITE http://www.dermcare.com.au SYNONYM(S) APVMA REGISTRATION NOs: 120mg capsules - 60618, 60mg capsules - 60619, 30mg capsules - 60620 USE(S) VETERINARY APPLICATIONS Oral capsules for the treatment of pituitary dependent and adrenal-dependent hyperadrenocorticism (Cushing’s Syndrome) in dogs. NOT CLASSIFIED AS HAZARDOUS ACCORDING TO NOHSC CRITERIA NOT CLASSIFIED AS A DANGEROUS GOOD BY THE CRITERIA OF THE ADG CODE UN NO. None Allocated DG CLASS None Allocated SUBSIDIARY RISK(S) None Allocated PKG GROUP None Allocated HAZCHEM CODE None Allocated EPG None Allocated INGREDIENT FORMULA CAS NO. CONTENT Trilostane C 20 -H 27 -N-O 3 13647-35-3 10mg or 30mg or 60mg or 120mg per capsule Non Hazardous Ingredients Not Available Not Available remainder EYE If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by the Poisons Information Centre or a doctor, or for at least 15 minutes. SKIN Gently flush affected areas with soap or mild detergent and plenty of water until no evidence of chemical remains (at least 15-20min). Seek medical attention if irritation develops. INHALATION Remove from exposure area to fresh air. If any symptoms persist Read the complete document
Brand name height = height of Cool Gray 50% Dechra Device. Strength is now 50% of initial brand name letter. Brand description is now 35% of initial brand name letter and has been moved up due to limited space. Brand name moved to 2 mm of cutter instead of letter width on front panel and tuck panel. Brand name and description moved down to accomodate warnings. Pictogram of dog made smaller and moved down because of limited space. Pantone reference guide 541 3395 CUTTER GUIDE VARNISH FREE 7659 Cool Gray 3 - 50% Cool Gray 3 - 20% Not to be printed Product: .......................... VETORYL 30 MG - AU - CARTON Dimensions:.............................................60 mm x 35 mm x 111 mm Primary brand name font size: ................................................. 36.8pt Primary brand description font size:..................................8pt and 9pt Body text font size: ....................................................................... 8pt Item code: ............................................................................... G1725 Pharmacode: ............................................................................... 192 Regulatory .................................................. Marketing ................................................... Technical .................................................... Date ........................... Date ........................... Date ........................... Date: Proof: 1 (NH) 2 3 (AD) 4 (NH) 5 (AD) 6 (CC) 7 (NH) 8 (NH) 9 (NH) 01-10-2014 01-10-2014 07-10-2014 09-10-2014 15-01-2016 22-01-2016 04-03-2016 04-03-2016 07-03-2016 Date: Proof: STYLE DEVIATIONS 541 - 50% 541 - 20% 541 - 30% V ETORYL ® 30 mg CAPSULES V ETORYL ® 30 mg CAPSULES 30 CAPSULES 30 mg PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY READ THE ENCLOSED LEAFLET BEFORE USING THIS PRODUCT. DIRECTIONS FOR USE: Contraindications: This product is contraindicated in animals suffering from primary hepatic disease and/or renal insufficiency. This product is contr Read the complete document